TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03328078: CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Sponsor: Curis, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 152 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT03328078 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03328078 Rescue Dossier →